JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
JOHNSON & JOHNSON
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026
$253.79−1.77 (-0.69%)
Close on Oct 19, 2026
- Market cap
- $619.27B
- P/E (TTM)
- 29.4
- Dividend yield
- 2.03%
JOHNSON & JOHNSON revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Innovative Medicine | $16.38B | $15.43B | $15.76B | $15.56B | $15.20B | $13.87B | $14.33B | $14.58B | $14.49B | $13.56B | $13.72B | $13.89B | 64.7% | +7.8% |
| MEDTECH | $8.93B | $8.64B | $8.80B | $8.43B | $8.54B | $8.02B | $8.19B | $7.89B | $7.96B | $7.82B | $7.67B | $7.46B | 35.3% | +4.5% |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Innovative Medicine | – | – | – | – | – | – | – | $4.48B | $5.46B | $4.97B | – | $4.79B | – |
| MEDTECH | – | – | – | – | – | – | – | $1.06B | $1.09B | $1.52B | – | $1.19B | – |
By product or service
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| U.S. [Member] | $14.53B | $13.33B | $14.20B | $13.71B | $13.54B | $12.31B | $13.20B | $12.91B | $12.57B | $11.62B | $12.01B | $12.00B | 57.4% | +7.3% |
| International | $10.78B | $10.73B | $10.37B | $10.29B | $10.20B | $9.59B | $9.32B | $9.56B | $9.88B | $9.76B | $9.39B | $9.36B | 42.6% | +5.7% |
| Europe | $5.73B | $5.85B | $5.60B | $5.44B | $5.39B | $5.11B | $4.92B | $4.91B | $5.21B | $5.16B | $4.96B | $4.73B | 22.6% | +6.3% |
| Asia-Pacific, Africa | $3.74B | $3.59B | $3.50B | $3.61B | $3.61B | $3.31B | $3.26B | $3.48B | $3.45B | $3.41B | $3.26B | $3.46B | 14.8% | +3.8% |
| Western Hemisphere, excluding U.S. | $1.31B | $1.29B | $1.27B | $1.23B | $1.21B | $1.17B | $1.14B | $1.17B | $1.21B | $1.19B | $1.17B | $1.17B | 5.2% | +8.5% |
From the segment and revenue-disaggregation notes of Johnson & Johnson's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.